Android app Apple app link

Amgen's Phase III trial of Imdelltra meets primary endpoint for SCLC

By Yahoo! Finance   |   1 month ago
Amgen's Phase III trial of Imdelltra meets primary endpoint for SCLC

Amgen's Phase III trial of Imdelltra in treating small cell lung cancer patients met its primary endpoint of improving overall survival. The therapy targets DLL3 protein and activates T cells to destroy cancer cells, showing promising clinical benefits.

Read More

Did you find this insightful?

Exclusive Content

Access to this content is reserved for premium members. Unlock all features by upgrading to a premium membership.

Get the App

To join as a premium member, please download our app and complete your membership purchase there.